FOSTER CITY, Calif. And HANGZHOU, ZHEJIANG, China, March 04, 2021 (GLOBE NEWSWIRE) – Announced Apollomics, Inc., an innovative biopharmaceutical company engaged in the discovery and development of mono- and combination-oncology treatments , today announced that the first patient was successfully enrolled in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsing or refractory acute myeloid leukemia (AML) in China . In February this year, the two Phase 1 survey sites were launched.
The Phase 1 clinical trial is part of the Phase 1 and Phase 3 bridge clinical trial of APL-106 in combination with chemotherapy in adults with recurrent or recurrent AML. Its principal investigator is Professor Jianxiang Wang from the Institute Hospital of Hematology and Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College. The main objective of Phase 1 is to study the pharmacokinetic (PK) properties of APL-106 in Chinese subjects with recurrent or recurrent AML and to assess the safety and tolerability of APL-106 in combination with chemotherapy.
About APL-106 (uproleselan injection)
APL-106 (uproleselan injection) is an innovative drug discovered and developed by GlycoMimetics. Uproleselan (yoo ‘pro le’ sel an) is designed to prevent E-selectin (molecular adhesion to cells in the bone marrow) from binding to blood cancer cells, thus disrupting machinery against leukemic cells within the bone marrow microenvironment. In 2017, the U.S. FDA granted the Breakthrough Therapy Specification to uproleselan for the treatment of adults with recurrent or refractory acute myeloid leukemia. Apollomics licensed uproleselan from GlycoMimetics in January 2020. Apollomics has rights to clinical development, production and commercial sales in the Chinese market (Mainland China, Hong Kong, Macau and Taiwan).
In September 2020, APL-106 received approval from the National Medical Products Administration (NMPA) through the issuance of a “Clinical Trial Drug Approval Notice”. This agreement enables a Phase I and Phase III clinical trial of APL-106 to be performed in combination with chemotherapy in adults with recurrent or refractory acute myeloid leukemia. In January 2021, APL-106 received a Breakthrough Therapy Specification with the Center for Drug Assessment (CDE) of the NMPA.
Mu Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow. It is an invasive disease that causes the bone marrow to secrete impure cells that cannot perform their normal function and become leukemia cells. In the U.S., there are approximately 20,000 new cases of AML each year, and the 5-year survival rate is 28.7%1. The annual incidence of AML in China in 2019 is around 26,9002, and recurrent / rescue AML has a very poor prognosis.
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies to utilize the immune system and to target specific molecular pathways to eliminate cancer. The company’s current pipeline is made up of several developmental stage assets incorporating modern human monoclonal antibodies that restore the body’s immune system to recognize and detect cancer cells. killing, and targeted treatments against uncontrolled growth signal pathways. For more information, visit www.apollomicsinc.com.
1National Institute of Cancer, Epidemiology, and Outcomes (SEER) Study Program
2Source: CIC Report
Contact information of Apollomics:
Contact an investor:
Wilson W. Cheung
Chief Financial Officer
Phone: + 1-650-209-4436
Email: [email protected]
Contact the company:
Remy Bernarda
Phone: + 1-415-203-6386
Email: [email protected]
Contact China Media:
Porda Havas International Financial Communications Agency
| Kelly Fung | Phoenix fungus | |
| General Manager | Vice President | |
| Phone: | (852) 3150 6763 | (852) 3150 6773 |
| Email: | [email protected] | [email protected] |